Home > Insider Trading > Filing (0001209191-20-065591)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1001233	Sangamo Therapeutics Inc	SGMO	Biological Products, (No Disgnostic Substances) (2836)	680359556

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1789340	Andrew Rolf Ramelmeier	C/O Sangamo Therapeutics, Inc. 7000 Marina Blvd Brisbane CA 94005	Evp, Technical Operations	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-12-24	3,331	$18.13	68,442	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

Includes: (a) 2,000 shares acquired by the Reporting Person on April 30, 2020; and (b) 645 shares acquired by the Reporting Person on October 30, 2020 under the Issuer's 2010 Employee Stock Purchase Plan, as amended.
Also included in this total are: (a) 8,333 shares from the Reporting Person's February 25, 2019 restricted stock unit (RSU) grant that will vest in two remaining annual installments on February 25, 2021 and February 25, 2022, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date; and (b) 55,000 shares from the Reporting Person's February 25, 2020 RSU grant that will vest in three annual installments on February 25, 2021, February 25, 2022 and February 25, 2023, resulting in such RSU grant being vested in full on the third (3rd) anniversary of the grant date.
All such RSUs are granted pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended") and vested or will vest with respect to 1/3rd of the shares in each respective RSU grant in three equal annual installments over the three-year period measured from the dates of grant, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended.